MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Apellis Pharmaceuticals Market Cap 2011-2026 | APLS
As of March 23, 2026 Apellis Pharmaceuticals has a market cap of $ 2.22 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.77 B | 3.08 B | 8.28 B | 6.45 B | 3.4 B | 3.33 B | 2.58 B | 738 M | 253 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.28 B | 253 M | 3.43 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
318 M | $ 3.45 | 3.29 % | $ 304 M |  USA |
 |
Amgen
AMGN
|
198 B | $ 351.92 | 1.18 % | $ 189 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 19.55 | 0.26 % | $ 914 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 218.41 | -1.57 % | $ 5 B |  Danmark |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.61 | - | $ 16.4 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Benitec Biopharma
BNTC
|
556 M | $ 11.01 | 0.27 % | $ 453 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Compugen Ltd.
CGEN
|
196 M | $ 2.08 | -0.48 % | $ 194 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.59 | 4.28 % | $ 186 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
28.2 M | $ 0.6 | -1.9 % | $ 6.87 M | Israel |
 |
Cellectis S.A.
CLLS
|
203 M | $ 3.37 | 0.75 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
898 M | $ 12.91 | 1.33 % | $ 778 M | USA |
 |
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | USA |
 |
CorMedix
CRMD
|
456 K | $ 6.32 | 1.12 % | $ 455 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
231 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
3.04 B | $ 20.96 | 3.92 % | $ 3.45 B | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.26 | 0.35 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |